Epstein–Barr virus associated CNS lymphoproliferative disorder after long-term immunosuppression

Lee, Andrew; Bridges, Leslie; Lloyd, Mark; Barker, Robert N.; Wren, Damian; Galtrey, Clare

doi:10.1136/practneurol-2019-002356

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…diarrhea, vomiting and mild abdominal pain), and mild lymphocytopenia can also occur. MMF increases the risk of lymphoproliferative disorders, especially in patients infected by Epstein-Barr virus 21,22 .…”

Section: Mycophenolate Mofetilmentioning

confidence: 99%

Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy

Abrantes

Moraes

Filho

et al. 2021

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.

show abstract

Section: Mycophenolate Mofetilmentioning

confidence: 99%